

詽

1 1

### British Orthopaedic Oncology Society

### DIGITAL PROGRAMME

Thursday 26th & Friday 27th June 2025 The Alex Hotel, Dublin



www.boos.org.uk

# PANTHEON®

Not all collars are created equal...



#### ADLER ORTHO UK Ltd

The Stables Tarvin Road Frodsham Cheshire WA6 6XN

Tel. 0151 329 3372 info@adlerorthouk.com www.adlerortho.com



### **Metastatic Bone Clinical Leaders Meeting**

Thursday 26th June 2025, The Alex Hotel, Dublin



09:00 - 09:50	Registration, Coffee and Refreshments
09:50 - 10:00	Welcome and introduction Prof Alan Molloy, National Orthopaedic Hospital Cappagh
10:00 - 10:15	MBD Evidence Summary 2024-5 Mr Jonathan MacDonald, Musgrave Park Hospital, Belfast
10:15 - 10:30	Myeloma for orthopaedic surgeons - the differences to MBD Dr Stella Bowcock, Consultant Haematologist, Kings College London
10:30 - 10:45	<b>The orthopaedic view on myeloma</b> Prof Rob Ashford, Leicester Orthopaedics
10:45 - 11:00	How I manage renal cell metastases Miss Martina Faimali, Royal National Orthopaedic Hospital
11:00 - 11:10	The ROH experience with a new custom implant provider Sponsored by:   Mr Scott Evans, Royal Orthopaedic Hospital Sponsored by:
	Session sponsored by Onkos Surgical
11:10 - 11:40	Morning Refreshments
11:40 - 11:55	Frailty in Metastatic Bone Disease Prof Rob Ashford, Leicester Orthopaedics
11:55 - 12:10	<b>Complexity classification in Metastatic Bone Disease</b> Mr Nomaan Sheikh, University Hospitals of Northampton
12:10 - 12:25	Malignancy of Unknown Origin / Carcinoma of unknown primary Mr Nicholas Eastley, Leicester Orthopaedics
12:25 - 12:40	<b>Developing consensus in MBD</b> Dr Rachel Baumber, Royal National Orthopaedic Hospital
12:40 - 13:30	Lunch
13:30 - 13:50	Challenges and Solutions on Improving the Outcomes for the METs PFR Patient Mr Lee Baylis, Royal National Orthopaedic Hospital, Stanmore
	Session sponsored by Adler Ortho & Fannin
13:50 - 15:10	Metastatic Bone Disease free paper session Chaired by: Mr Sam McMahon, Miss Harriet Branford-White
13.50	Periprosthetic fractures around megaprostheses of the knee for oncological indications: A comparison of treatment modalities - Jonathan Stevenson, Royal Orthopaedic Hospital Birmingham

13.58	<i>Metastatic bone disease in a regional centre: 10 -year analysis of surgical procedures, complications and survival outcomes - Eric Anyanwu, Oxford University Hospitals NHS Foundation Trust</i>
14.06	<i>Multidisciplinary Management of Metastatic Bone Disease- a Survey of Current Practice in the UK</i> - Jonathan Sterne, Musgrave Park Hospital, Belfast
14.14	<b>The experiences of a metastatic bone disease fellow in a UK sarcoma centre</b> - Alastair Beaven, The Royal Orthopaedic Hospital Birmingham
14.22	<b>A Dedicated Metastatic Bone Disease Clinic Reduces Mortality in Post-Surgical Patients</b> - Ranga Benamanahally, Royal National Orthopaedic Hospital
14.30	Surgery for metastatic cancer: Are we reducing life expectancy by improving quality? - Sophie McGrann, Sheffield Teaching Hospitals
14.38	<b>"Intralesional Arthroplasty" in Patients with Metastatic Bone Disease – A Boon in the Surgical Multimodal Management of Cancer Patients</b> - Rajkumar Gangadharan, Liverpool University Hospital NHS Foundation Trust
14.46	<b>A description of urgent metastatic bone disease referrals to a UK specialist sarcoma centre</b> - Alastair Beaven, ROH Birmingham
14.54	<b>What is a wide margin when resecting renal-cell bone metastases?</b> Jonathan Stevenson, Royal Orthopaedic Hospital Birmingham
15.02	<b>Results of surgical stabilisation in patients with metastatic bone disease – 12 year experience from a regional metastatic unit</b> - Saif UI Islam, Liverpool University Hospitals NHS Foundation Trust
15:10 - 15:25	10 year results of management of Metastatic Bone Disease from a regional metastatic unit - Liverpool model Mr Birender Kapoor, Royal Liverpool and Broadgreen University Hospitals NHS Trust
15:25 - 15:40	Afternoon refreshments
15:40 - 15:50	Feedback on BOOS Diploma Prof Tom Cosker, Oxford University Hospitals
15:50 - 16:00	Management of Metastatic Disease in UK. Whither are we bound? Mr. Birender Kapoor, Royal Liverpool and Broadgreen University Hospitals NHS Trust Session sponsored by: implantcast
16:00 - 16:10	PORTRAIT Trial Mr Jonathan Stevenson, Royal Orthopaedic Hospital Birmingham
16:10 - 16:25	<b>Controversies in Metastatic Bone Disease</b> Miss Louise McCullough, NHS Grampian and Albyn Hospital
16:25 - 17:15	<b>The Great Debate: Oligometastatic disease, Fix or Replace?</b> Mr Rob Pollock, Royal National Orthopaedic Hospital - Advocating for endoprosthetic replacement Mr Max Vaynrub, Memorial Sloan Kettering Cancer Center - Advocating for osteosynthesis
17:15	Closing Remarks
17:20 - 18:00	
	BOOS Board Meeting (closed meeting)

## **BOOS Conference Programme** Friday 27th June 2025, The Alex Hotel, Dublin



08:15 - 08:50	Registration, Coffee and Refreshments
08:45 - 08:50	Welcome to the Annual BOOS Conference 2025 Rob Pollock, President of BOOS
08:50 - 09:15	<b>Predicting outcomes in patients with osteosarcoma</b> Prof Adrienne Flanagan, Royal National Orthopaedic Hospital Stanmore
09:15 - 10:11	Free Paper Session 1 Chairpersons : Mr Max Vaynrub & Mr Sanjay Gupta
09:15 - 09:23	<b>Outcome, Complications, and Survival of Sarcomas of the Extremities Treated With Mega</b> <b>Prostheses: A Comprehensive Analysis of 115 Cases in a Cancer-Dedicated Hospital</b> - Khalil Farooque, Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore
09:23 - 09:31	<b>Total Femoral Replacement: Salvaging the unsalvageable – or not?</b> - Rob Ashford, Leicester Hip & Oncology Group
09:31 - 09:39	<b>Initial Performance and Early Patient Outcomes of the ADLER Pantheon Megaprosthesis</b> - Bisola Salaja, RCSI
09:39– 09:47	Endoprosthetic Reconstruction Using the Global Modular Replacement System (GMRS) or Stanmore Modular Endoprosthetic Tumour System (METS): Outcomes Equally Good for Oncological and Non-oncological Indications, and Improved With Hydroxyapetite Coating - Gareth Turnbull, NHS Lothian
09:47 - 09:55	<b>Outcome of composite proximal tibial and distal femoral endoprosthetic reconstruction in oncological patients</b> - Charles Baird, Royal Orthopaedic Hospital Birmingham
09:55 - 10:03	<i>Early outcomes of Adler Pantheon modular femoral EPR compared with Stanmore Mets prosthesis</i> - Gill Cribb, Robert Jones and Agnes Hunt Orthopaedic Hospital
10:03 - 10:11	Distal Femoral Replacement: Are You Rotating it Right? Unlocking Precision with the Linea Aspera - Kostas Dogramatzis, Nuffield Orthopaedic Centre, OUH
10:15 - 10:20	<b>Update on SUNDIAL Trial</b> Mr Sanjay Gupta, Glasgow Royal Infirmary
10:25 - 10:45	Emerging Surgical Techniques in Sarcoma Prof Carol Morris, Memorial Sloan Kettering Cancer Centre
10:45 - 11:05	Morning Refreshments and Poster Viewing
11:05 - 11:15	Feedback on BOOS Diploma Prof Tom Cosker, Oxford University Hospitals
11:15 - 11:35	Pulmonary Metastatic disease in sarcoma – how we deal with it Prof David Healy, Consultant Cardiothoracic Surgeon, St.Vincent's Hospital Dublin

11:35 - 12:30	Free Paper Session 2 Chairpersons: Ms Gill Cribb & Prof Tom Cosker
11.35 - 11.43	<b>The Role of Thoracic Surgery Within A National Sarcoma Service</b> - Patrick Kennelly, St Vincents University Hospital
11.43 - 11.51	Surgical and Oncological Outcomes Following Resection and Reconstruction of Bony Chest Wall (Ribs, Clavicle, or Sternum) for Non-Metastatic Chest Wall Sarcomas - Jessica Lei Chen, University of Glasgow
11.51 - 11.59	<b>Outcome of a non-invasive expandable prosthesis in paediatric bone sarcoma patients</b> - Yuval Fuchs MD, National Unit of Orthopedic Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
11.59 -12.07	<b>Local experience of LINK custom prosthesis for malignant primary bone tumours</b> - Cliodhna Ni Fhoghlu, National Orthopaedic Hospital Cappagh
12.07-12.15	<b>A review of paediatric orthopaedic oncology in Ireland 2018-2025</b> - Cliodhna Ni Fhoghlu, National Orthopaedic Hospital Cappagh
12.15-12.23	<i>Implant survival and acetabular complications in paediatric proximal femoral endoprostheses</i> - Charles Baird, Royal Orthopaedic Hospital, Birmingham
12.30 - 13.00	<b>BOOS INVITATIONAL LECTURE</b> <b>Orthopaedic Toxicities from Cancer Care: Implications for Survivorship</b> Prof Carol Morris, Memorial Sloan Kettering Cancer Centre
13:00 - 14:00	Lunch and Poster Viewing13:30BOOS AGM
14:00 - 14:30	After lunch speech with David O'Leary - former premier league footballer player Includes question and answer session
14:30 - 14:45	<b>BOA Future leaders programme</b> Ashley Scrimshire, Newcastle NHS Trust & Vlad Paraoan, Oxford University Hospitals NHS Trust
14:40 - 15:45	Free Paper Session 3 Chairpersons: Mr Kenny Rankin & Mr Tom Hilton
14.40-14.48	The Effect of Rising Rates of Urgent Suspected Cancer Referrals on Waiting Times at a Tertiary Sarcoma Centre - Sarah Thomson, University of Aberdeen, School of Medicine, Aberdeen
14.48-14.57	Gait, Balance, and Physical Activity in Patients with Proximal Tibial Replacements after Musculoskeletal Tumours - A Multidimensional Functional Outcome Assessment using the STanmore OutcoMes Project (STOMP) - Sherron Furtado, Royal National Orthopaedic Hospital
14.57-15.05	<b>Balance, Gait, and Biomechanical Compensations Developed During Different Speeds of Walking After Treatment for Distal Femoral Malignant Bone Tumours</b> - Sherron Furtado, Royal National Orthopaedic Hospital
15.05-15.13	<b>Evaluating management of Extra-abdominal Desmoid Fibromatosis: A Retrospective Analysis of treatments, Outcomes and Recurrence Pattern</b> - Sanjay Gupta, Glasgow Royal Infirmary
15.13-15.21	Trainees' perspective of Orthopaedic Oncology - Thomas O Neill, St. Vincent's University Hospital
15.21-15.29	<b>The Surgical Training in AMPutation Care (STAMP-C) Study – A National Cross-Sectional Survey of Trauma and Orthopaedic Trainees in the United Kingdom and Ireland</b> - Matthew Arnaouti, Royal National Orthopaedic Hospital

15.29-15.37	<b>Real-World Monitoring Of Physical Activity Using an Accelerometer after Lower Limb</b> <b>Surgery for a Sarcoma</b> - Sherron Furtado, Royal National Orthopaedic Hospital
15:45 - 16:00	Afternoon Refreshments and Poster Viewing
16:00 - 16:15	<b>The South African Sarcoma Registry</b> Mr Tom Hilton, Consultant Orthopaedic Surgeon Groote Schuur Hospital, Cape Town
16:15 - 17:00	Free Paper Session 4 Chairpersons: Ms Heledd Havard & Prof Gary O'Toole
16.15-16.23	Impact of Surgical Advancements and Treatment Paradigms on Survival Outcomes in Pelvic Sarcoma A Comparative Analysis of Modern and Historical Cohorts - Lee Jeys, Royal Orthopaedic Hospital
16.23-16.31	Surgical and functional outcomes of resections in Pelvic Sarcoma: Experience From A Dedicated Cancer Hospital - Khalil Farooque, Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore
16.31-16.39	<b>Evaluating Outcomes for Primarily Unresectable Chondrosarcoma</b> - Lee Jeys, Royal Orthopaedic Hospital
16.39-16.47	<b>Use of Smartbone in Orthopaedic Oncology. A Case Series</b> - Karen Shepherd, The Robert Jones and Agnes Hunt Orthopaedic Hospital
16.47-16.55	<i>Focal synovially-based lesions in the kneehow often are they malignant?</i> - Charles Baird, Royal Orthopaedic Hospital, Birmingham
17:00 - 17:15	Closing remarks – prize giving & BOOS Fellowship Awards

### Posters



#### 1. Developing Consensus-Based National Rehabilitation Guidelines in Musculoskeletal Oncology.

Abby McCarthy, Royal National Orthopaedic Hospital NHS Trust, Stanmore

### 2. Service Improvement Audit of 2WW referrals at a District General Hospital

Bill Robertson-Smith, Northampton General Hospital

#### 3. Haematoma or sarcoma?

Catharine Berry, University Hospitals Leicester

#### 4. Handcrafted Bone Cement Spacer as a Reliable Alternative for Proximal Humerus Reconstruction Following Wide Tumor Resection

Hassan Mohammed Hassan Elbahri, College of Medicine and Health Sciences (CMHS)-Arabian Gulf University (AGU)- Manamah , Bahrain

#### 5. Late Onset (More than 3 Decades) Skeletal Mets after invasive ductal Carcinoma, A Report of case and Literature Review

Hozifa Mohammed Ali Abdelmaged, Alzaiem Alazhari University, Sudan

#### 6. The Impact of War on Musculoskeletal Oncology Surgery in Sudan: Challenges, Consequences, and Case Presentations

Hozifa Mohammed Ali Abdelmaged, Alzaiem Alazhari University, Sudan

#### 7. A survey of patient experiences of communication with healthcare providers in the diagnosis of musculoskeletal tumours

implantcast

Joseph McKay, NHS Greater Glasgow & Clyde

### 8. Reverse polarity shoulder replacement in orthopaedic oncology. Presentation of a case series of patients highlighting tumour and shoulder surgeon surgical collaboration.

Karen Shepherd, The Robert Jones and Agnes Hunt Orthopaedic Hospital

### 9. Chemical adjuvants in the surgical treatment of GCT-B

Kostas Dogramatzis, Nuffield Orthopaedic Centre

### 10. Brown Cell Tumour – an atypical presentation

Maria Clara Correia, ULS São João, Porto, Portugal

#### 11. The tibia is the bone of the devil

Megan Scotcher, Leicester Orthopaedics, University Hospitals of Leicester NHS Trust

### 12. Surgical Treatment of TGCT Knee: One-stage, two-stage, open or arthroscopic. A proposal

Robert U Ashford, Leicester Orthopaedics, East Midlands Sarcoma Service

### 13. Proximal femur surgery at RNOH in 2024: A review

Shea Byrne, Royal National Orthopaedic Hospital

### 14. Chest metastasis in giant cell tumour of bone – fact or myth?

Sherif Ahmed Kamel, Royal Orthopaedic Hospital

15. Experience of physical disabilities and cancer-related quality of life after spinal tumors - A national survey in England Sherron Furtado, Royal National Orthopaedic Hospital NHS Trust

# 16. What are the experiences of gait, activity levels, and physical functioning in proximal femoral replacement after musculoskeletal tumors?

Sherron Furtado, Royal National Orthopaedic Hospital NHS Trust

### 17. Hand Tumours: A Retrospective Analysis of Aetiology and Referral Pathways Safety

Tanmay Jitendra Talavia, University Hospitals of Leicester NHS Trust

### 18. Evolving Paradigms in the Treatment of Osteoid Osteoma: A Systematic Review of Minimally Invasive and Noninvasive Modalities

Ufaq Taufiq, University Hospital Waterford



# Complete intra-operative flexibility, fixation and infection prevention

Our endo-prosthetic replacements include proximal femoral, distal femoral, proximal tibial and humeral replacements. Together with MUTARS silver technology to fight infection\* and 3D-printed, modular EPORE collars that improve osteo-integration\*\*, these are a comprehensive solution, designed to provide complete intra-operative flexibility.

\*Hardes J, von Eiff C, Streitbuerger A, Balke M, Budny T, Henrichs MP, Hauschild G, Ahrens H. Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol. 2010 Apr 1;101(5):389-95 \*\*Haider T, Pagkalos I, Morris G, Parry MC, Jeys LM. Early radiographic osseointegration of a novel highly porous 3D-printed titanium collar for megaprostheses compared to a previous generation smooth HA-coated collar. Arch Orthop Trauma Surg. 2023 Jan 4.





### **Together Delivering...**

### Surgeon-Driven, Patient-Inspired Solutions

### My3D<sup>®</sup> Personalized Revision Cup<sup>™</sup> (PRC<sup>™</sup>)

- Simplifies acetabular revision procedures
- CT-based digital planning ensures optimal defect fill, orientation and offset, implant fit, and targeted screw fixation
- 3D printed with BioGrip® porous structure to support bone ingrowth



#### My3D<sup>®</sup> Personalized Solutions

3D printed, patient-specific solutions for pelvic and long bone reconstruction

- Dedicated Patient Solutions engineer
- 3D printed osteotomy instrumentation
- 3D Anatomic Modeling



#### JTS Extendible Prosthesis

- Implant can be extended over time without surgical intervention, in a clinical setting
- Helps reduce the risk of complications associated with limb reconstruction surgery in pediatric cancer patients
- Extensive clinical history with demonstrated results

Disclaimer: Onkos Surgical, BioGrip, My3D, Personalized Revision Cup and PRC are registered marks and trademarks of Onkos Surgical. A surgeon should rely on his or her own professional medical/clinical judgement when deciding which particular product to use when treating a patient. Onkos Surgical does not prescribe medical advice and advocates that surgeons be trained in the use of any particular product before using it in surgery. A surgeon must always refer to the product label and/or instructions for use before using any Onkos Surgical product.

©2025. Onkos Surgical, Inc. All Rights Reserved. CORP 06.16.25 vO



### Visit idealMed and Onkos at BOOS 2025

Stand 8 and 9

